{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:31:26Z","timestamp":1760142686746,"version":"build-2065373602"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004889","name":"Fondation CHU de Qu\u00e9bec","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004889","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.biopha.2021.111232","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T02:32:31Z","timestamp":1610591551000},"page":"111232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic"],"prefix":"10.1016","volume":"137","author":[{"given":"Ruixuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preyesh","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenfa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9149-375X","authenticated-orcid":false,"given":"Sheng-Xiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2021.111232_bib0005","article-title":"Brief review on COVID-19: the 2020 pandemic caused by SARS-CoV-2","volume":"12","author":"Valencia","year":"2020","journal-title":"Cureus."},{"key":"10.1016\/j.biopha.2021.111232_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1142\/S0192415X20500378","article-title":"COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-western medicine for the management of 2019 novel coronavirus disease","volume":"48","author":"Chan","year":"2020","journal-title":"Am. J. Chin. Med."},{"key":"10.1016\/j.biopha.2021.111232_bib0015","first-page":"1","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak \u2013 an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.biopha.2021.111232_bib0020","first-page":"1","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"6736","author":"Chan","year":"2020","journal-title":"Lancet (London, England)."},{"key":"10.1016\/j.biopha.2021.111232_bib0025","first-page":"1","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"6736","author":"Lu","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.biopha.2021.111232_bib0030","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.tim.2016.03.003","article-title":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","volume":"24","author":"Su","year":"2016","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.biopha.2021.111232_bib0035","first-page":"4430","article-title":"Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks","author":"Zhang","year":"2020","journal-title":"J. Phys. Chem. Lett."},{"year":"2020","series-title":"COVID-19 Drug Therapy \u2013 Potential Options","author":"Smith","key":"10.1016\/j.biopha.2021.111232_bib0040"},{"key":"10.1016\/j.biopha.2021.111232_bib0045","unstructured":"ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/results?cond=COVID-19 (accessed April 8, 2020)."},{"key":"10.1016\/j.biopha.2021.111232_bib0050","article-title":"Early empirical assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020","author":"Leung","year":"2020","journal-title":"MedRxiv Prepr."},{"key":"10.1016\/j.biopha.2021.111232_bib0055","series-title":"Statement on AstraZeneca Oxford SARS-CoV- 2 Vaccine, AZD1222, COVID-19 Vaccine Trials Temporary Pause","first-page":"2","author":"AstraZeneca","year":"2020"},{"key":"10.1016\/j.biopha.2021.111232_bib0060","first-page":"1","article-title":"COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing","author":"To","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"80-","key":"10.1016\/j.biopha.2021.111232_bib0065","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.biopha.2021.111232_bib0070","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2021.111232_bib0075","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/emboj\/cdf327","article-title":"Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain","volume":"21","author":"Anand","year":"2002","journal-title":"EMBO J."},{"key":"10.1016\/j.biopha.2021.111232_bib0080","article-title":"Design of wide-spectrum inhibitors targeting coronavirus main proteases","volume":"3","author":"Yang","year":"2005","journal-title":"PLoS Biol."},{"issue":"80-","key":"10.1016\/j.biopha.2021.111232_bib0085","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"4489","author":"Dai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.biopha.2021.111232_bib0090","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.biopha.2021.111232_bib0095","first-page":"1","article-title":"Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus","author":"Liu","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.biopha.2021.111232_bib0100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds","volume":"115","author":"B\u00e1ez-Santos","year":"2015","journal-title":"Antiviral Res."},{"issue":"80-","key":"10.1016\/j.biopha.2021.111232_bib0105","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.biopha.2021.111232_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12688\/f1000research.22457.2","article-title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates","volume":"9","author":"Chen","year":"2020","journal-title":"F1000Research"},{"key":"10.1016\/j.biopha.2021.111232_bib0115","first-page":"1","article-title":"Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants","author":"Tahir ul Qamar","year":"2020","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.biopha.2021.111232_bib0120","first-page":"1","article-title":"Homology models of the papain-like protease PLpro from coronavirus 2019-nCoV","author":"Stoermer","year":"2019","journal-title":"ChemRxiv"},{"key":"10.1016\/j.biopha.2021.111232_bib0125","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1128\/JVI.02322-09","article-title":"Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family coronaviridae","volume":"84","author":"O\u2019Keefe","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2021.111232_bib0130","article-title":"The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity","author":"Zhang","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.biopha.2021.111232_bib0135","article-title":"Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2","author":"Korber","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.biopha.2021.111232_bib0140","series-title":"SARS-COV-2 RBD DMS 2020","first-page":"1","author":"Bloom","year":"2020"},{"key":"10.1016\/j.biopha.2021.111232_bib0145","article-title":"Modelling conformational state dynamics and its role on infection for SARS-CoV-2 Spike protein variants","author":"Teruel","year":"2020","journal-title":"BioRxiv Prepr."},{"issue":"80-","key":"10.1016\/j.biopha.2021.111232_bib0150","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Science"},{"year":"2020","series-title":"A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19","author":"Lilly","key":"10.1016\/j.biopha.2021.111232_bib0155"},{"key":"10.1016\/j.biopha.2021.111232_bib0160","article-title":"First antibody trial launched in COVID-19 patients","author":"Droit","year":"2020","journal-title":"Sci. Mag."},{"issue":"80-","key":"10.1016\/j.biopha.2021.111232_bib0165","article-title":"Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail","volume":"0827","author":"Hansen","year":"2020","journal-title":"Science"},{"issue":"80-","key":"10.1016\/j.biopha.2021.111232_bib0170","article-title":"Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies","volume":"0831","author":"Baum","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.biopha.2021.111232_bib0175","article-title":"SARS-CoV-2 Spike protein variant D614G increases infectivity and retains sensitivity to antibodies that target the receptor binding domain","author":"Yurkovetskiy","year":"2020","journal-title":"BioRxiv Prepr. Serv. Biol."},{"key":"10.1016\/j.biopha.2021.111232_bib0180","first-page":"1","article-title":"A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses","volume":"6","author":"Zhao","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2021.111232_bib0185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.biopha.2021.111232_bib0190","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.biopha.2021.111232_bib0195","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/nar\/gkp904","article-title":"The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent","volume":"38","author":"te Velthuis","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"80-","key":"10.1016\/j.biopha.2021.111232_bib0200","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"1560","author":"Yin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.biopha.2021.111232_bib0205","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2005.02.017","article-title":"Expression, purification, and characterization of SARS coronavirus RNA polymerase","volume":"335","author":"Cheng","year":"2005","journal-title":"Virology."},{"key":"10.1016\/j.biopha.2021.111232_bib0210","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1126\/science.abb9332","article-title":"Rapid repurposing of drugs for COVID-19","volume":"368","author":"Guy","year":"2020","journal-title":"Science."},{"key":"10.1016\/j.biopha.2021.111232_bib0215","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","author":"Riva","year":"2020","journal-title":"Nature."},{"key":"10.1016\/j.biopha.2021.111232_bib0220","doi-asserted-by":"crossref","first-page":"228","DOI":"10.47108\/jidhealth.Vol3.Iss4.71","article-title":"Treatment of coronavirus disease 2019: a comprehensive review","volume":"3","author":"Sosyal","year":"2020","journal-title":"J. Ideas Heal."},{"key":"10.1016\/j.biopha.2021.111232_bib0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"MBio."},{"key":"10.1016\/j.biopha.2021.111232_bib0230","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.biopha.2021.111232_bib0235","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2021.111232_bib0240","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1074\/jbc.AC120.013056","article-title":"The antiviral compound remdesivir potently inhibits RNAdependent RNA polymerase from Middle East respiratory syndrome coronavirus","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2021.111232_bib0245","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1093\/nar\/gkg916","article-title":"Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design","volume":"31","author":"Xu","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2021.111232_bib0250","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1093\/nar\/12.18.7269","article-title":"Primary structural comparison of RNA-dependent polymerases from plant, animal and bacterial viruses","volume":"12","author":"Kamer","year":"1984","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2021.111232_bib0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2020.107695","article-title":"Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation","volume":"100","author":"Kato","year":"2020","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.biopha.2021.111232_bib0260","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/prot.20194","article-title":"Human SARS-coronavirus RNA-dependent RNA polymerase: Activity determinants and nucleoside analogue inhibitors","volume":"57","author":"Azzi","year":"2004","journal-title":"Proteins Struct. Funct. Genet."},{"key":"10.1016\/j.biopha.2021.111232_bib0265","series-title":"First Case of 2019 Novel Coronavirus in the United States","first-page":"1","author":"Lofy","year":"2020"},{"key":"10.1016\/j.biopha.2021.111232_bib0270","unstructured":"ClinicalTrials.gov, (n.d.). https:\/\/www.clinicaltrials.gov\/ct2\/results?cond=Coronavirus&term=&type=&rslt=&age_v=&gn dr=&intr=remdesivir&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfp (accessed September 11, 2020)."},{"year":"2020","series-title":"NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19","key":"10.1016\/j.biopha.2021.111232_bib0275"},{"key":"10.1016\/j.biopha.2021.111232_bib0280","first-page":"1","article-title":"Remdesivir for the treatment of Covid-19 \u2014 preliminary report","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.111232_bib0285","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 \u2014 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2021.111232_bib0290","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101710","article-title":"Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence","volume":"35","author":"Khambholja","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"10.1016\/j.biopha.2021.111232_bib0295","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","article-title":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model","volume":"105","author":"Oestereich","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.biopha.2021.111232_bib0300","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Japan Acad. Ser. B."},{"key":"10.1016\/j.biopha.2021.111232_bib0305","first-page":"19","article-title":"Emerging evidence-basedtherapies in COVID-19","volume":"19","author":"Pareek","year":"2020","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.biopha.2021.111232_bib0310","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2217\/fvl.14.66","article-title":"The RNA-dependent RNA polymerase of the influenza A virus","volume":"9","author":"Stubbs","year":"2014","journal-title":"Future Virol."},{"key":"10.1016\/j.biopha.2021.111232_bib0315","first-page":"1","article-title":"Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection","volume":"0","author":"Du","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2021.111232_bib0320","article-title":"Role of favipiravir in the treatment of COVID-19","author":"Joshi","year":"2020","journal-title":"International Society for Infectious Diseases"},{"key":"10.1016\/j.biopha.2021.111232_bib0325","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell."},{"key":"10.1016\/j.biopha.2021.111232_bib0330","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","author":"Gordon","year":"2020","journal-title":"Nature, Nature."},{"key":"10.1016\/j.biopha.2021.111232_bib0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcimb.2020.00317","article-title":"ACE2, Much More Than Just a Receptor for SARS-COV-2","volume":"10","author":"Samavati","year":"2020","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.biopha.2021.111232_bib0340","first-page":"1","article-title":"Human recombinant soluble ACE2 in severe COVID-19","volume":"2600","author":"Zoufaly","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.biopha.2021.111232_bib0345","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2021.111232_bib0350","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s13054-020-03078-z","article-title":"Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series","volume":"24","author":"Doi","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.biopha.2021.111232_bib0355","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","article-title":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J. Virol."},{"year":"2020","series-title":"SARS-CoV-2 Invades Host Cells Via a Novel Route: CD147-Spike Protein","author":"Ke Wang","key":"10.1016\/j.biopha.2021.111232_bib0360"},{"year":"2020","series-title":"Meplazumab Treats COVID-19 Pneumonia: an Open-labelled, Concurrent Controlled Add-on Clinical Trial","author":"Bian","key":"10.1016\/j.biopha.2021.111232_bib0365"},{"key":"10.1016\/j.biopha.2021.111232_bib0370","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","article-title":"A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells","volume":"78","author":"Hoffmann","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2021.111232_bib0375","series-title":"Brief Report: Rapid Clinical Recovery From Critical COVID-19 With Respiratory Failure in a Lung Transplant Patient Treated With Intravenous Vasoactive Intestinal Peptide","first-page":"1","author":"Georges Youssef","year":"2020"},{"key":"10.1016\/j.biopha.2021.111232_bib0380","unstructured":"S. de Crescenzo, Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID, Xconomy Natl. (n.d.)."},{"key":"10.1016\/j.biopha.2021.111232_bib0385","unstructured":"H. Slater, FDA Accepts IND for NK Cell Therapy CYNK-001 to Treat Patients with COVID- 19, Immuno Oncol. News. (n.d.) 2\u20135."},{"key":"10.1016\/j.biopha.2021.111232_bib0390","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.7150\/ijbs.45538","article-title":"Traditional chinese medicine in the treatment of patients infected with 2019-New coronavirus (SARS-CoV-2): a review and perspective","volume":"16","author":"Yang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.biopha.2021.111232_bib0395","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ptr.1485","article-title":"Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS","volume":"18","author":"Chen","year":"2004","journal-title":"Phyther. Res."},{"key":"10.1016\/j.biopha.2021.111232_bib0400","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.joim.2020.02.004","article-title":"Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)","volume":"18","author":"quan Ling","year":"2020","journal-title":"J. Integr. Med."},{"key":"10.1016\/j.biopha.2021.111232_bib0405","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.joim.2020.02.005","article-title":"In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus","volume":"18","author":"hai Zhang","year":"2020","journal-title":"J. Integr. Med."},{"year":"2020","series-title":"Press Conference of the Joint Prevention and Control Mechanism of State Council on Feb 17, 2020.","author":"Publicity Department of the People\u2019s Republic of China","key":"10.1016\/j.biopha.2021.111232_bib0410"},{"key":"10.1016\/j.biopha.2021.111232_bib0415","article-title":"Traditional Chinese medicine for COVID-19 treatment","volume":"155","author":"ling Ren","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2021.111232_bib0420","first-page":"1","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","author":"Shen","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.biopha.2021.111232_bib0425","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","article-title":"A novel coronavirus outbreak of global health concern","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet."},{"key":"10.1016\/j.biopha.2021.111232_bib0430","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","article-title":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment","volume":"14","author":"Wang","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.biopha.2021.111232_bib0435","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","article-title":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment","volume":"14","author":"Wang","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.biopha.2021.111232_bib0440","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.biopha.2021.111232_bib0445","article-title":"An hACE2 peptide mimic blocks SARS-CoV-2 pulmonary cell infection","author":"Karoyan","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.biopha.2021.111232_bib0450","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/antib8040053","article-title":"Engineering a novel antibody-peptide bispecific fusion protein against MERS-CoV","volume":"8","author":"Wang","year":"2019","journal-title":"Antibodies."},{"key":"10.1016\/j.biopha.2021.111232_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v9090255","article-title":"Identification of a novel inhibitor against middle east respiratory syndrome coronavirus","volume":"9","author":"Sun","year":"2017","journal-title":"Viruses."},{"key":"10.1016\/j.biopha.2021.111232_bib0460","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1021\/jm200870n","article-title":"Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors","volume":"54","author":"Akaji","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2021.111232_bib0465","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/14756366.2019.1690480","article-title":"Inhibition of SARS-CoV 3CL protease by flavonoids","volume":"35","author":"Jo","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.biopha.2021.111232_bib0470","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","author":"Ma","year":"2020","journal-title":"BioRxiv."},{"key":"10.1016\/j.biopha.2021.111232_bib0475","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1016\/j.bmcl.2017.04.056","article-title":"Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor","volume":"27","author":"Konno","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2021.111232_bib0480","article-title":"Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L","author":"Sacco","year":"2020","journal-title":"BioRxiv"},{"key":"10.1016\/j.biopha.2021.111232_bib0485","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejmech.2017.05.045","article-title":"Discovery of unsymmetrical aromatic disulfides as novel inhibitors of SARS-CoV main protease: chemical synthesis, biological evaluation, molecular docking and 3D-QSAR study","volume":"137","author":"Wang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2021.111232_bib0490","article-title":"A speedy route to multiple highly potent SARS-CoV-2 main protease inhibitors","author":"Yang","year":"2020","journal-title":"BioRxiv Prepr. Serv. Biol."},{"key":"10.1016\/j.biopha.2021.111232_bib0495","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/14756366.2014.1003215","article-title":"Chalcones isolated from Angelica keiskei inhibit cysteine proteases of SARS-CoV","volume":"31","author":"Park","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.biopha.2021.111232_bib0500","article-title":"3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice","volume":"5332","author":"Rathnayake","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2021.111232_bib0505","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1080\/14756366.2020.1801672","article-title":"Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro","volume":"35","author":"Jo","year":"2020","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.biopha.2021.111232_bib0510","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.antiviral.2014.12.011","article-title":"Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus","volume":"115","author":"Cheng","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.biopha.2021.111232_bib0515","article-title":"Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs","author":"Arya","year":"2020","journal-title":"Chemrxiv.Org."},{"key":"10.1016\/j.biopha.2021.111232_bib0520","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1016\/j.bmc.2012.07.038","article-title":"Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases","volume":"20","author":"Park","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2021.111232_bib0525","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1248\/bpb.b12-00623","article-title":"Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus","volume":"35","author":"Park","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.biopha.2021.111232_bib0530","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.bmc.2013.03.027","article-title":"Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa","volume":"21","author":"Cho","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2021.111232_bib0535","doi-asserted-by":"crossref","first-page":"5228","DOI":"10.1021\/jm900611t","article-title":"Structure-based design, synthesis, and biological evaluation of a series of novel and reversible inhibitors for the severe acute respiratory syndrome - coronavirus papain-like protease","volume":"52","author":"Ghosh","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2021.111232_bib0540","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1021\/jm1004489","article-title":"Severe acute respiratory syndrome coronavirus papain-like novel protease inhibitors: design, synthesis, protein-ligand X-ray structure and biological evaluation","volume":"53","author":"Ghosh","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2021.111232_bib0545","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm401712t","article-title":"X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases","volume":"57","author":"B\u00e1ez-Santos","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2021.111232_bib0550","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","article-title":"Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes","volume":"150","author":"Lin","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.biopha.2021.111232_bib0555","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/j.bmcl.2015.05.039","article-title":"Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity","volume":"25","author":"Peters","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2021.111232_bib0560","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.4014\/jmb.1507.07078","article-title":"Identification of a novel small molecule inhibitor against SARS coronavirus helicase","volume":"25","author":"Cho","year":"2015","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.biopha.2021.111232_bib0565","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1016\/j.ejmech.2011.09.005","article-title":"2,6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV)","volume":"46","author":"Kim","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.biopha.2021.111232_bib0570","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1128\/AAC.00957-12","article-title":"Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase","volume":"56","author":"Adedeji","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2021.111232_bib0575","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.4014\/jmb.1707.07073","article-title":"A novel chemical compound for inhibition of SARS coronavirus helicase","volume":"27","author":"Lee","year":"2017","journal-title":"J. Microbiol. Biotechnol."},{"key":"10.1016\/j.biopha.2021.111232_bib0580","doi-asserted-by":"crossref","DOI":"10.1007\/s13238-020-00768-w","article-title":"Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2","author":"Xiong","year":"2020","journal-title":"Protein Cell"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221000172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332221000172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:14:48Z","timestamp":1760098488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332221000172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":116,"alternative-id":["S0753332221000172"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111232","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2021.111232","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"111232"}}